Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Ann Thorac Cardiovasc Surg. 2022 Oct 20;28(5):320-328. doi: 10.5761/atcs.oa.22-00058. Epub 2022 May 28.
We aimed to verify the prognosis of epidermal growth factor receptor (EGFR) mutation of clinical (c)-stage IA lung adenocarcinoma with the ground-glass opacity (GGO) component.
We evaluated 226 cases of surgically resected c-stage IA lung adenocarcinoma with GGO component. Endpoints were overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier analysis and the log-rank test were used to estimate the survival differences. Prognostic factors were assessed using the univariable and multivariable Cox proportional hazards model.
Among the 226 cases, 177 cases harbored the EGFR-mutant adenocarcinoma with the GGO component. The mean duration of follow-up time was 54.4 ± 1.2 months. The 5-year OS and RFS did not differ significantly between the EGFR-mutant and wild-type groups (5-year OS 100% vs. 94.3%, hazard ratio [HR] 0.276, P = 0.168; 5-year RFS 94.7% vs. 95.7%, HR 0.873, P = 0.864). Multivariable Cox hazard model revealed that radiologically solid component size (P = 0.010) and pathological node-positive (P = 0.036) were significant predictors of an inferior RFS.
EGFR-mutant was not a prognostic factor of OS and RFS for c-stage IA lung adenocarcinoma with the GGO component. Radiologically solid component size and pathological lymph node status were independent prognostic factors of worse RFS.
我们旨在验证具有磨玻璃成分（GGO）的临床（c）-IA 期肺腺癌中表皮生长因子受体（EGFR）突变的预后。
我们评估了 226 例经手术切除的具有 GGO 成分的 c-IA 期肺腺癌病例。终点是总生存期（OS）和无复发生存期（RFS）。使用 Kaplan-Meier 分析和对数秩检验来估计生存差异。使用单变量和多变量 Cox 比例风险模型评估预后因素。
在 226 例病例中，177 例存在具有 GGO 成分的 EGFR 突变型腺癌。中位随访时间为 54.4±1.2 个月。EGFR 突变型和野生型组之间的 5 年 OS 和 RFS 无显著差异（5 年 OS 100% vs. 94.3%，风险比[HR]0.276，P=0.168；5 年 RFS 94.7% vs. 95.7%，HR 0.873，P=0.864）。多变量 Cox 风险模型显示，影像学实性成分大小（P=0.010）和病理淋巴结阳性（P=0.036）是 RFS 较差的显著预测因素。
EGFR 突变不是具有 GGO 成分的 c-IA 期肺腺癌 OS 和 RFS 的预后因素。影像学实性成分大小和病理淋巴结状态是 RFS 较差的独立预后因素。
